$12.85
-0.32 (-2.43%)
Elan Corp, plc (ADR) (NYSE:ELN)
CAPS Rating:
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
RSS Headlines
Fool UK
Recs
A high risk high reward company with a very promising pipeline, in particular for Alzheimer's and multiple sclerosis. The recent Tysabri scare that precipitated its sudden drop was a huge overreaction by the investor community. While its fundamentals are not up to par compared with other premier pharma co's, it is way oversold and a great buy at its current levels.